Orris

Treatment of adpkd

Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed

"autosomal dominant polycystic kidney disease" AND treatment

Searching the Web

ADPKD management treatment KDIGO 2025 tolvaptan blood pressure

Reading File
Reading File
Finding Sources
Reading Web Page

https://kdigo.org/wp-content/uploads/2025/01/KDIGO-2025-ADPK…

Treatment of autosomal dominant polycystic kidney disease (ADPKD)

Management aims to slow loss of kidney function, treat complications, and prepare for kidney replacement therapy if needed. Care should be coordinated with a nephrologist.

1. Slow disease progression

Risk-stratify first
  • Use serial eGFR, kidney imaging with height-adjusted total kidney volume and the Mayo Imaging Classification, and sometimes the PROPKD score.
  • This identifies people likely to have rapid progression and who may benefit from disease-modifying therapy.
Tolvaptan
  • A vasopressin V2-receptor antagonist and the main disease-modifying drug for adults at risk of rapid progression.
  • KDIGO recommends offering it when eGFR is at least 25 mL/min/1.73 m² and there is evidence of rapid progression, such as Mayo class 1C-1E or an eGFR decline of at least 3 mL/min/1.73 m²/year.
  • Typically started at 45 mg in the morning plus 15 mg about 8 hours later, then titrated if tolerated.
  • Expected effect: slows kidney-volume growth and the decline in eGFR. The 2024 Cochrane review supports tolvaptan as the best-established pharmacologic option for slowing progression (PMID: 39356039).
  • Important adverse effects: marked thirst and frequent urination, dehydration, hypernatremia, gout, and potentially serious liver injury.
  • Check liver tests before treatment, monthly for the first 18 months, then every 3 months. It should not be used in pregnancy, while breastfeeding, with significant liver disease, urinary obstruction, inability to maintain water intake, or use of strong CYP3A inhibitors. See the KDIGO tolvaptan recommendations.
Lifestyle and kidney protection
  • Control body weight, avoid smoking, exercise regularly, limit dietary sodium, and avoid dehydration.
  • Adequate water intake is encouraged, but it must be individualized, particularly in advanced CKD, heart failure, or hyponatremia risk. Water intake is not a replacement for tolvaptan in a person eligible for it.
  • Avoid nephrotoxins where possible, especially NSAIDs, and adjust medication doses to eGFR.

2. Treat hypertension aggressively

Hypertension is common and accelerates kidney and cardiovascular damage.
  • Use home and clinic BP monitoring.
  • ACE inhibitors or ARBs are generally preferred, especially with albuminuria.
  • Add other agents as needed, often a calcium-channel blocker or diuretic.
  • BP targets should be individualized by age, CKD stage, tolerance, and symptoms. KDIGO emphasizes regular monitoring, lifestyle measures, and medication when needed in ADPKD. See the KDIGO 2025 executive summary.

3. Manage renal and extra-renal complications

ProblemUsual approach
Flank/abdominal painExclude stone, cyst bleeding, infection, or obstruction. Start with acetaminophen and non-drug measures. Avoid long-term NSAIDs. Refractory pain may need pain specialists, cyst aspiration/sclerotherapy, or surgery in selected cases.
Cyst hemorrhage / hematuriaUsually rest, hydration if appropriate, analgesia, and temporary avoidance of anticoagulants if clinically safe. Persistent or severe bleeding needs evaluation for stones, tumor, or other causes.
Cyst or urinary infectionUrine culture and antibiotics. Suspected cyst infection needs agents with good cyst penetration and prolonged treatment under specialist guidance.
Kidney stonesHydration when appropriate, metabolic assessment, analgesia, and standard stone treatment.
Polycystic liver diseaseUsually observation. Treat symptomatic large cysts or severe mass effect with specialist options such as aspiration-sclerotherapy, fenestration, hepatic resection, or rarely transplant.
Intracranial aneurysmScreening is not routine for every patient. It is considered with a personal history of subarachnoid hemorrhage, family history of aneurysm/SAH/unexplained sudden death, or selected high-risk settings.

4. When kidney failure develops

  • Prepare early for kidney transplantation or dialysis.
  • Pre-emptive kidney transplantation is preferred when feasible.
  • Both hemodialysis and peritoneal dialysis can be used.
  • Native-kidney removal is not routine, but may be needed for recurrent infection or bleeding, severe pain, lack of transplant space, or suspected malignancy.

Treatments not routinely used to slow kidney decline

Current KDIGO guidance does not recommend mTOR inhibitors, metformin, statins, SGLT2 inhibitors, somatostatin analogues, ketogenic diets, or complementary therapies solely to slow ADPKD progression outside appropriate indications or research settings. The KDIGO treatment summary makes this distinction explicitly.
Practical next steps: confirm eGFR and urine albumin, measure home BP, obtain or review MRI-based Mayo classification, review family history of aneurysm, and discuss eligibility for tolvaptan with nephrology.
This is a shared conversation. Sign in to Orris to start your own chat.